Posted by Michael Wonder on 04 Feb 2021
Innovent and Lilly jointly announce the approval of Tyvyt (sintilimab) by China NMPA in combination with pemetrexed and platinum chemotherapy as first-line therapy for non-squamous non-small cell lung cancer
3 February 2021 - Innovent Biologics and Eli Lilly today jointly announced that the National Medical Products Administration of China has approved the supplemental new drug application of Tyvyt (sintilimab) in combination with pemetrexed and platinum chemotherapy as first-line therapy for people with non-squamous non-small-cell lung cancer.
This is the second approved indication of Tyvyt (sintilimab) in China, following the first approved indication by the National Medical Products Administration in December 2018 for the treatment of relapsed or refractory classical Hodgkin's lymphoma after at least two lines of systemic chemotherapy.
